Short Interest in IceCure Medical Ltd (NASDAQ:ICCM) Drops By 52.3%

IceCure Medical Ltd (NASDAQ:ICCM) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 285,500 shares, a decline of 52.3% from the February 28th total of 598,100 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 378,700 shares, the short-interest ratio is currently 0.8 days.

IceCure Medical Trading Up 0.5 %

Shares of ICCM traded up $0.01 during trading on Friday, reaching $1.11. 221,593 shares of the company traded hands, compared to its average volume of 521,961. The stock has a market cap of $61.61 million, a PE ratio of -3.83 and a beta of 0.37. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. IceCure Medical has a twelve month low of $0.48 and a twelve month high of $1.66. The stock has a 50-day simple moving average of $1.32 and a 200-day simple moving average of $0.98.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Thursday, March 27th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. On average, analysts anticipate that IceCure Medical will post -0.28 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.50 price target on shares of IceCure Medical in a report on Friday.

Institutional Trading of IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC lifted its stake in IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 40,453 shares of the company’s stock after acquiring an additional 14,893 shares during the period. Geode Capital Management LLC owned 0.07% of IceCure Medical worth $44,000 at the end of the most recent reporting period. 0.62% of the stock is currently owned by institutional investors.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.